Ciclesonide
- Generic Name
- Ciclesonide
- Brand Names
- Alvesco, Omnaris, Zetonna
- Drug Type
- Small Molecule
- Chemical Formula
- C32H44O7
- CAS Number
- 126544-47-6
- Unique Ingredient Identifier
- S59502J185
- Background
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
- Indication
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
- Associated Conditions
- Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 5000
- Registration Number
- NCT04870333
- Locations
- 🇬🇧
Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust, King's Lynn, United Kingdom
🇬🇧University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
🇬🇧Imperial College Healthcare NHS Trust, London, United Kingdom
Inhaled Ciclesonide for Outpatients With COVID19
- Conditions
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 215
- Registration Number
- NCT04435795
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦McGill University Health Center, Montreal, Quebec, Canada
🇨🇦Sunnybrook Hospital, Toronto, Ontario, Canada
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Covis Pharma S.à.r.l.
- Target Recruit Count
- 400
- Registration Number
- NCT04377711
- Locations
- 🇺🇸
University of Buffalo, Buffalo, New York, United States
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 412
- Registration Number
- NCT04356495
- Locations
- 🇫🇷
Bordeaux university Hospital, Bordeaux, France
🇫🇷CNGE, Paris, France
🇫🇷CHU de Montpellier, Montpellier, France
The Mannitol-Asthma-Ciclesonide-Study
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Cantonal Hosptal, Baselland
- Target Recruit Count
- 72
- Registration Number
- NCT03839433
Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT02665806
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02221375
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
- Conditions
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT02155881
Effect of High Dose Ciclesonide on Asthma Control
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 520
- Registration Number
- NCT01455194
Omnaris Versus Levocetirizine Phase 4 Study
- Conditions
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT01430260
- Locations
- 🇰🇷
handok pharmaceuticals co. LTD, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.